Hydroxyzine revealing acquired neuromuscular weakness in a patient with COVID-19 disease

Mohamed Bahi MD, Younes Aissaoui MD, Ayoub Belhadj MD, Youssef Qamouss MD, Rachid Seddiki MD

ABSTRACT

Acquired neuromuscular weakness often develops in patients with an acute respiratory distress syndrome (ARDS), in particular in patients who are ventilated and sedated for long periods. This has been rarely described in the literature on ARDS secondary to SARS-CoV-2 infection. Our clinical case revealed the existence of these neuromuscular manifestations in the COVID-19 disease after the use of hydroxyzine, an antihistamine whose respiratory side-effects are unknown.

Keywords: Neuromuscular weakness, COVID-19, hydroxyzine, hypercapnia.

Article citation: Bahi M, Aissaoui Y, Belhadj A, Qamouss Y, Seddiki R. Hydroxyzine revealing acquired neuromuscular weakness in a patient with COVID-19 disease. The Southwest Respiratory and Critical Care Chronicles 2021;9(40):74–76
From: Anesthesiology and Intensive Care Unit, Avicenne Military Hospital, Cadi Ayyad University, Marrakesh, Morocco
Submitted: 5/15/2021
Accepted: 6/22/2021
Reviewer: Kenneth Nugent MD
Conflicts of interest: none
This work is licensed under a Creative Commons
Attribution-Share A like 4.0 International License.